US 11,696,937 B2
Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof
Chang Shao, Shanghai (CN); Mei Ge, Shanghai (CN); Lingao Ruan, Shanghai (CN); Wei Wei, Shanghai (CN); Xing Xia, Shanghai (CN); Min Rao, Shanghai (CN); Qingqian Meng, Shanghai (CN); and Minyu Luo, Shanghai (CN)
Assigned to Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd., Zhejiang (CN); and Zhejiang Medicine Co., Ltd., Zhejiang (CN)
Appl. No. 16/978,688
Filed by Shanghai LaiYi Center For Biopharmaceutical R&D Co, Shanghai (CN); and Zhejiang Medicine Co., Ltd., Shaoxing (CN)
PCT Filed Mar. 4, 2019, PCT No. PCT/CN2019/076826
§ 371(c)(1), (2) Date Sep. 5, 2020,
PCT Pub. No. WO2019/170046, PCT Pub. Date Sep. 12, 2019.
Claims priority of application No. 201810183928.6 (CN), filed on Mar. 6, 2018.
Prior Publication US 2021/0093691 A1, Apr. 1, 2021
Int. Cl. A61K 38/14 (2006.01); A61P 31/04 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01)
CPC A61K 38/14 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01); A61P 31/04 (2018.01)] 2 Claims
 
1. A glycopeptide compound having activity of resisting drug-resistant bacteria of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), characterized in that, conforming glycopeptide compounds shown in general formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R represents by the following formula: -A-D-E-G; wherein:
A is a benzene ring;
D is —O— or —NH—;
E is —(CH2)m-, wherein m is 1 to 3;
G is the structural formula:

OG Complex Work Unit Chemistry
wherein L is any one of halogen, trifluoromethyl, and methoxy.